A trial to compare piperacillin/tazobactam and cefepime for the treatment of AmpC-inducible enterobacteriaceae infections

Trial Profile

A trial to compare piperacillin/tazobactam and cefepime for the treatment of AmpC-inducible enterobacteriaceae infections

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2016

At a glance

  • Drugs Cefepime (Primary) ; Piperacillin/tazobactam (Primary)
  • Indications Enterobacteriaceae infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 May 2016 New trial record
    • 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top